Allogene Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • June 4th, 2020 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 4th, 2020 Company Industry JurisdictionAllogene Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 11,702,128 shares of the Company’s common stock, par value $0.001 per share (“Stock”, and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to 1,755,319 additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).